| 000 | 01907 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250514011855.0 | ||
| 264 | 0 | _c20011101 | |
| 008 | 200111s 0 0 eng d | ||
| 022 | _a1524-4628 | ||
| 024 | 7 |
_a10.1161/hs1001.096003 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKapadia, S R | |
| 245 | 0 | 0 |
_aInitial experience of platelet glycoprotein IIb/IIIa inhibition with abciximab during carotid stenting: a safe and effective adjunctive therapy. _h[electronic resource] |
| 260 |
_bStroke _cOct 2001 |
||
| 300 |
_a2328-32 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Controlled Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAbciximab |
| 650 | 0 | 4 |
_aAdjuvants, Pharmaceutic _xtherapeutic use |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 |
_aBlood Vessel Prosthesis Implantation _xadverse effects |
| 650 | 0 | 4 |
_aCarotid Artery Diseases _xsurgery |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGraft Occlusion, Vascular _xetiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin Fab Fragments _xadverse effects |
| 650 | 0 | 4 |
_aIntracranial Hemorrhages _xetiology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aPlatelet Glycoprotein GPIIb-IIIa Complex _xantagonists & inhibitors |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aStents _xadverse effects |
| 650 | 0 | 4 |
_aThromboembolism _xetiology |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aUrokinase-Type Plasminogen Activator _xtherapeutic use |
| 700 | 1 | _aBajzer, C T | |
| 700 | 1 | _aZiada, K M | |
| 700 | 1 | _aBhatt, D L | |
| 700 | 1 | _aWazni, O M | |
| 700 | 1 | _aSilver, M J | |
| 700 | 1 | _aBeven, E G | |
| 700 | 1 | _aOuriel, K | |
| 700 | 1 | _aYadav, J S | |
| 773 | 0 |
_tStroke _gvol. 32 _gno. 10 _gp. 2328-32 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1161/hs1001.096003 _zAvailable from publisher's website |
| 999 |
_c11508638 _d11508638 |
||